Plain-English translation of NCT07464132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is evaluating a new imaging technology called [68Ga]Ga-NI-FAPI-04 PET/CT that can help doctors see and diagnose diseases related to fibroblast activation — abnormal scarring cells that can damage organs like the heart, lungs, and blood vessels. The medication works as a tracer that lights up areas where these problematic cells are active, making them visible on a special type of scan. Researchers want to determine whether this imaging method can reliably diagnose fibroblast-related conditions that are currently difficult to detect.
Many serious conditions — including certain cancers, heart diseases, and lung scarring — involve fibroblasts, but doctors don't have a reliable way to spot and measure this activity early on. This medication aims to fill that gap by making fibroblast activity visible, which could lead to earlier diagnosis and better treatment planning.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the imaging medication, then undergo a PET/CT scan — a special imaging test that combines two types of scans to show where fibroblasts are active in your body. The study involves about 30 participants total, and you'll need to be able to return for follow-up visits to complete the research. The entire process is non-invasive; the main thing you'll do is lie still during the imaging scan while the machine takes pictures.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China